T2000 in Essential Tremor - Open Label Continuation
NCT00655278 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5
Last updated 2013-12-23
Summary
This study will evaluate the safety and efficacy of T2000 when used to treat patients with moderate to severe essential tremor over an 18 month period.
Conditions
Interventions
- DRUG
-
T2000
T2000 at previous most effective, well-tolerated dose (600-1000mg daily)
Sponsors & Collaborators
-
Sun Pharmaceutical Industries, Inc.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-08-31
- Primary Completion
- 2009-11-30
- Completion
- 2009-12-31
Countries
- Canada
Study Locations
More Related Trials
-
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease
NCT02373072 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate SAGE-217 in Participants With Essential Tremor
NCT02978781 ·Status: COMPLETED ·Phase: PHASE2
-
Intermittent Oral Administration vs. Semi-continuous Intra-oral Administration of Levodopa/Carbidopa in Fluctuating Parkinsonian Patients
NCT02763137 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess Safety and Efficacy of Surgical Implant of RNDP-001 in Patients With Idiopathic Parkinson's Disease
NCT07106021 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
DNS-7801 vs. Placebo in Parkinson's Disease
NCT03306329 ·Status: TERMINATED ·Phase: PHASE2
-
Phase I Open-label Study of Low-dose Ketamine Infusion Treatment in Levodopa-Induced Dyskinesia in Parkinson's Disease
NCT06021756 ·Status: UNKNOWN ·Phase: PHASE1
-
A Phase 2 Trial Evaluating SNC-102 in Drug-Induced Tardive Dyskinesia
NCT02064010 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's Disease
NCT00866502 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes
NCT01950455 ·Status: TERMINATED ·Phase: PHASE3
-
Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's Disease
NCT06356662 ·Status: RECRUITING ·Phase: PHASE1
-
A Single Oral Dose, Crossover Comparative PK Study of WD-1603 in Healthy Subjects Under Fasting Conditions
NCT04553978 ·Status: UNKNOWN ·Phase: PHASE1
-
Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease (PD) and End-of-dose Wearing Off
NCT00601978 ·Status: WITHDRAWN ·Phase: PHASE4
-
Topiramate as a Treatment for Levodopa-Induced Dyskinesia in Parkinson's Disease
NCT00296959 ·Status: TERMINATED ·Phase: PHASE2
-
A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD
NCT04993755 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of AAV-hAADC-2 in Subjects With Parkinson's Disease
NCT00229736 ·Status: COMPLETED ·Phase: PHASE1
-
Assessing the Pharmacokinetics, Safety, Tolerability and Efficacy of Continuous Oral Levodopa Via the DopaFuse® Delivery System in Parkinson's Disease Patients
NCT04778176 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Assess the Clinical Benefit and Safety of Droxidopa in Parkinson's Disease
NCT02066571 ·Status: UNKNOWN ·Phase: PHASE2
-
Phase 2a Study of VTX3232 in Parkinson's Disease
NCT06556173 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's Disease
NCT00006077 ·Status: COMPLETED ·Phase: PHASE2
-
JP-1730 to Treat Parkinson's Disease
NCT00040209 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease
NCT05642442 ·Status: COMPLETED ·Phase: PHASE2
-
Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease
NCT01789047 ·Status: TERMINATED ·Phase: PHASE2
-
Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's Disease
NCT01806896 ·Status: COMPLETED ·Phase: PHASE2
-
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease
NCT05686551 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Safety, Tolerability and Efficacy of AVP-786 for the Treatment of Disinhibition
NCT02534038 ·Status: TERMINATED ·Phase: PHASE2